Hugel Inc (145020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hugel Inc (145020) has a cash flow conversion efficiency ratio of 0.066x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩64.74 Billion ≈ $43.88 Million USD) by net assets (₩980.16 Billion ≈ $664.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hugel Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Hugel Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hugel Inc total liabilities for a breakdown of total debt and financial obligations.
Hugel Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hugel Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
0.004x |
|
Sanquan Food Co Ltd
SHE:002216
|
0.057x |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
0.047x |
|
Galapagos N.V.
AS:GLPG
|
-0.022x |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
N/A |
|
UIE PLC
CO:UIE
|
0.044x |
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
N/A |
|
Carabao Group Public Company Limited
BK:CBG-R
|
0.092x |
Annual Cash Flow Conversion Efficiency for Hugel Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Hugel Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Hugel Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩980.16 Billion ≈ $664.24 Million |
₩150.06 Billion ≈ $101.69 Million |
0.153x | -13.64% |
| 2024-12-31 | ₩840.81 Billion ≈ $569.81 Million |
₩149.05 Billion ≈ $101.01 Million |
0.177x | +17.42% |
| 2023-12-31 | ₩779.68 Billion ≈ $528.38 Million |
₩117.71 Billion ≈ $79.77 Million |
0.151x | +48.32% |
| 2022-12-31 | ₩792.11 Billion ≈ $536.80 Million |
₩80.63 Billion ≈ $54.64 Million |
0.102x | -7.96% |
| 2021-12-31 | ₩777.09 Billion ≈ $526.62 Million |
₩85.94 Billion ≈ $58.24 Million |
0.111x | +11.14% |
| 2020-12-31 | ₩746.67 Billion ≈ $506.01 Million |
₩74.30 Billion ≈ $50.35 Million |
0.100x | -9.59% |
| 2019-12-31 | ₩699.50 Billion ≈ $474.04 Million |
₩76.99 Billion ≈ $52.18 Million |
0.110x | +21.74% |
| 2018-12-31 | ₩727.72 Billion ≈ $493.17 Million |
₩65.80 Billion ≈ $44.59 Million |
0.090x | -2.01% |
| 2017-12-31 | ₩695.71 Billion ≈ $471.47 Million |
₩64.19 Billion ≈ $43.50 Million |
0.092x | -48.33% |
| 2016-12-31 | ₩252.80 Billion ≈ $171.32 Million |
₩45.14 Billion ≈ $30.59 Million |
0.179x | +87.79% |
| 2015-12-31 | ₩207.85 Billion ≈ $140.85 Million |
₩19.76 Billion ≈ $13.39 Million |
0.095x | -52.12% |
| 2014-12-31 | ₩53.21 Billion ≈ $36.06 Million |
₩10.57 Billion ≈ $7.16 Million |
0.199x | -- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more